IP Library Granted Patent US 10,258,580
Granted Patent B2
US 10,258,580 · App. 14/128,208 · Granted Apr 16, 2019

Cannabinoids for use in the treatment of neurodegenerative diseases or disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,258,580
App. No.
14/128,208
Granted
Apr 16, 2019
Kind
B2
Abstract

The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.

Claims (10)

1. A method for treating neurodegenerative diseases or disorders comprising administering to a subject in need thereof a therapeutically effective amount of cannabinoids cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA), wherein the CBDV and/or CBDVA are isolated or purified.

2. The method of claim 1 , wherein the cannabinoid is CBDV.

3. The method of claim 1 , wherein the cannabinoid is CBDVA.

4. The method of claim 1 , wherein the neurodegenerative disease or disorder is selected from the group consisting of: Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis; and Huntington's disease.

5. The method of claim 4 , wherein the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.

6. The method of claim 1 , wherein the cannabinoid/s are administered in a daily dose effective to prevent or treat neurodegenerative diseases or disorders.

7. The method of claim 6 , wherein the effective daily dose of cannabinoid/s is between 5 mg and 1000 mg.

8. The method of claim 7 , wherein the effective daily dose of cannabinoid/s is between 10 mg and 50 mg.

9. The method of claim 1 , further comprising administering the cannabinoid/s in combination with one or more other medicinal substances.

10. The method of claim 1 , wherein the cannabinoid/s are in the form of a botanical drug substance (BDS).

Assignments (3)
CHANGE OF NAME Recorded May 13, 2025
From: GW PHARMA LIMITED
To: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED
Reel/Frame 071097/0088 →
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2014
From: IUVONE, TERESA; DI MARZO, VINCENZO; GUY, GEOFFREY; WRIGHT, STEPHEN; STOTT, COLIN
To: GW PHARMA LIMITED
Reel/Frame 033231/0026 →
Cited By (2)
US 12,275,914 US 12,465,589